Brain‐targeting drug delivery systems

Liu, Peixin; Jiang, Chen

doi:10.1002/wnan.1818

Cited by 24 publications

(6 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This phenomenon is mainly due to the following issues, including the presence of the BBB, the heterogeneity of tumor tissues, and the complexity of the tumor microenvironment. Accordingly, the following attempts may be the key to overcoming these issues: (1) It is highly necessary to develop more effective drug delivery systems, research on which has progressed tremendously and has been detailed in the excellent reviews [ 97 , 98 , 99 , 100 ]; (2) for the complex heterogeneity of tumors, more systematic molecular pathological and mechanistic studies are effective. For example, as WHO CNS5 is published, Gene and Protein Nomenclature is formally recommended and verified to be more clinically effective and beneficial.…”

Section: Summary and Perspectivementioning

confidence: 99%

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

Wang

Yue

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common primary central nervous system tumor, whose prognosis remains poor under the sequential standard of care, such as neurosurgery followed by concurrent temozolomide radiochemotherapy and adjuvant temozolomide chemotherapy in the presence or absence of tumor treating fields. Accordingly, the advent of molecular targeted therapy and immunotherapy has opened a new era of tumor management. A diverse range of targeted drugs have been tested in patients with GBM in phase III clinical trials. However, these drugs are ineffective for all patients, as evidenced by the fact that only a minority of patients in these trials showed prolonged survival. Furthermore, there are several published phase III clinical trials that involve immune checkpoint inhibitors, peptide vaccines, dendritic cell vaccines, and virotherapy. Accordingly, this review comprehensively overviews existing studies of targeted drugs and immunotherapy for glioma and discusses the challenge and perspective of targeted drugs and immunotherapy for glioma to clarify future directions.

show abstract

Section: Summary and Perspectivementioning

confidence: 99%

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

Wang

Yue

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

show abstract

“…These traditional non-invasive strategies to overcome the barrier include the injection of hypertonic agents such as mannitol, the administration of vasoactive compounds like bradykinin or focused ultrasound. The mechanical effect of sound waves on brain vasculature produce the biological effect of transient BBB opening (Liu & Jiang, 2022). For instance, magnetic resonance-guided focused ultrasound (MRgFUS) has been widely used for drugs, gene and stem cell delivery in CNS (Stavarache et al, 2021).…”

Section: The Global Impact Of Neurodegenerative Diseases: Prevalence ...mentioning

confidence: 99%

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Hernando

Santos‐Vizcaíno

Igartua

et al. 2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) are an accelerating global health problem as life expectancy rises worldwide. Despite their significant burden in public health systems to date, the existing treatments only manage the symptoms without slowing down disease progression. Thus, the ongoing neurodegenerative process remains untreated. Moreover, the stronghold of the brain—the blood–brain barrier (BBB)—prevents drug penetrance and dwindles effective treatments. In the last years, nanotechnology‐based drug delivery systems (DDS) have become a promising approach to target and treat these disorders related to the central nervous system (CNS). PLGA based nanoparticles (NPs) were the first employed DDS for effective drug delivery. However, the poor drug loading capacity and localized immunogenicity prompted the scientific community to move to another DDS such as lipid‐based NPs. Despite the lipid NPs' safety and effectiveness, their off‐target accumulation together with the denominated CARPA (complement activation‐related pseudo allergy) reaction has limited their complete clinical translation. Recently, biological NPs naturally secreted by cells, termed as extracellular vesicles (EVs) have emerged as promising more complex biocompatible DDS. In addition, EVs act as dual players in NDs treatment, as a “cell free” therapy themselves, as well as new biological NPs with numerous characteristics that qualify them as promising carriers over synthetic DDS. The present review aims to display advantages, drawbacks, current limitations and future prospective of the previously cited synthetic and biological DDS to enter the brain and treat one of 21st century most challenging diseases, NDs.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

“…As drug carriers, they can prolong the half‐life of drugs and improve their utilization to achieve effective targeted delivery and reduce their side effects on normal tissues 8,9 . In addition, functionally engineered nanoparticles allow drugs crossing the blood–brain barrier (BBB) to enter into the brain effectively 10,11 . Over the past 30 years, several nanomaterials have been approved by Food and Drug Administration, including liposomes, polymers/micelles, iron oxides, mesoporous silica, and gold NPs 12 .…”

Section: Introductionmentioning

confidence: 99%

“…8,9 In addition, functionally engineered nanoparticles allow drugs crossing the blood-brain barrier (BBB) to enter into the brain effectively. 10,11 Over the past 30 years, several nanomaterials have been approved by Food and Drug Administration, including liposomes, polymers/ micelles, iron oxides, mesoporous silica, and gold NPs. 12 The flexibility in the design and modification of nanomaterials makes them very attractive in the treatment of various diseases in the complex biological microenvironment, such as cancer, 13 cardiovascular diseases, 14 and neurodegenerative diseases.…”

mentioning

confidence: 99%

Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson's disease by advanced nanoparticles

Liu

Hua

Zheng

et al. 2023

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

With the aging of global population, the early diagnosis and treatment of neurodegenerative diseases such as Parkinson's disease (PD) have attracted considerable attention. Despite great advances achieved during the past decades, PD as the second largest neurodegenerative disease is still incurable. In the clinical practice, PD patients are mainly treated by drugs, and supplemented with deep brain stimulation or nerve nucleus destruction. The existing drugs can only relieve the symptoms of motor disorder, and cannot stop the progression of PD. Compared with small molecular drugs, nanoparticles exhibit multiple functions in the neuroprotection and neurorepair due to their tunable physical and chemical properties, easy modification and functionalization. Herein, we first briefly review the characteristics of nanoparticles crossing the blood–brain barrier, which is a primary challenge for the treatment of PD. Then, we summarize the pathologic mechanisms of PD and comprehensively discuss the novel PD therapy based on diverse nanoparticles, including alleviating oxidative stress, scavenging α‐synuclein aggregates, chelating metal ions, delivering neurotrophic factors and genes, and transplanting stem cells. This review aims to highlight the great potential of advanced nanoparticles in the therapy of PD.

show abstract

Brain‐targeting drug delivery systems

Cited by 24 publications

References 206 publications

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles—Focus on Alzheimer's and Parkinson's disease

Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson's disease by advanced nanoparticles

Contact Info

Product

Resources

About